BIONEER CORPORATION

Founded in 1992 as Korea's first biotech venture company, BIONEER develops and manufactures life science reagents, instruments and services built on core genomic technologies including DNA synthesis, PCR, DNA sequencing and siRNA, serving customers in more than 50 countries. The company also advances RNAi therapeutics through its proprietary SAMiRNA platform, and through subsidiary siRNAgen Therapeutics is developing RNAi-based treatments for fibrosis, oncology, obesity and other diseases, with lead candidate SRN-001 for idiopathic pulmonary fibrosis having completed Phase 1a trials and advancing to Phase 1b.